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BAVITUXIMAB
Bavituximab is a chimeric IgG1 monoclonal antibody 
against anionic phospholipids expressed on the tumor endothe-
lium. Binding of bavituximab to a complex of phosphatidyl-
serine and the β2 glycoprotein 1 leads to antibody-dependent 
cellular cytotoxicity, resulting in vascular destruction. The 
selective activity in malignant cells occurs because of the fact 
that phosphatidylserine, the primary target of bavituximab, is 
restricted to the inner membrane leaflet in normal cells and 
becomes exposed to the outer leaflet during physiological 
stress and hypoxia, which are common events in cancer cells. 
In the phase I trial,1 26 patients were treated in four dose-esca-
lation cohorts from 0.1 mg/kg to 3 mg/kg weekly. Treatment 
was well tolerated with the only dose-limiting toxicity being a 
case of pulmonary embolism occurring in the 3 mg/kg cohort. 
In a phase II trial, the combination of paclitaxel 175 mg/m2 
plus carboplatin area under the curve 5 every 3 weeks plus 
bavituximab 3 mg/kg weekly, resulted in overall response rate 
of 43% in 49 patients with advanced non–small-cell lung 
cancer (NSCLC), with median progression-free survival and 
overall survival (OS) of 6.1 and 12.4 months, respectively.
Dr. Gerber presented an update on a randomized phase II 
trial in which 86 patients with nonsquamous NSCLC received 
either carboplatin plus paclitaxel alone or with bavituximab. 
The primary endpoint was response rate. In the preliminary 
report, the response rates for chemotherapy alone and with 
bavituximab were 26% and 39% respectively, suggesting a 
potential benefit in the experimental arm. A three-arm study 
comparing docetaxel alone, with bavituximab at 1 mg/kg 
weekly or 3 mg/kg weekly in the second-line setting has com-
pleted accrual of 121 patients, with results expected soon.
IMETELSTAT
Human telomeres are tandem arrays of the hexameric 
sequence TTAGGG associated with the protein complex shel-
terin at the ends of chromosomes. With each cell division, 
there is a shortening of the telomeric repeats, with growth 
arrest and senescence occurring when a few telomeres become 
critically short. Tumor cells may overcome the telomere short-
age-induced growth arrest by up-regulation of telomerase, a 
cellular ribonucleoprotein enzyme that adds TTAGGG repeats 
to the 3´ ends of the chromosomes.2 Because telomerase is 
detected in approximately 90% of malignant tumors, it repre-
sents a very attractive target for therapy. 
Dr. Schiller presented the data on imetelstat (GRN 
163L), a 13-mer oligonucleotide that is complementary to the 
template region of telomerase RNA, acting as a competitive 
inhibitor and preventing the telomeres elongation. In a phase 
Ib study, the combination of paclitaxel, carboplatin, and ime-
telstat at escalating doses from 3.2 mg/kg to 13.5 mg/kg was 
well tolerated with delayed myelossupression as the most sig-
nificant toxicity, requiring a change in the imetelstat admin-
istration from days 1, 8, and 15 to days 1 and 8 only, with 
cycles repeating every 21 days. Imetelstat is also being tested 
as a maintenance therapy in patients without disease progres-
sion after four cycles of carboplatin plus paclitaxel, with or 
without bevacizumab. With 56 patients enrolled, neutropenia 
and thrombocytopenia were more frequent in patients receiv-
ing maintenance imetelstat plus bevacizumab, compared with 
each drug alone or observation.
DASATINIB
Dasatinib is a potent src family kinases inhibitor that is 
currently approved for the treatment of chronic myeloid leu-
kemia and Philadelphia chromosome positive acute lympho-
blastic leukemia. Single-agent dasatinib had modest activity 
in unselected patients with NSCLC, although marked activ-
ity in one patient and prolonged stable disease (SD) in four 
patients of a total of 34 enrolled patients suggested a potential 
subpopulation that may benefit from this drug.3
Dr. Johnson presented preclinical data on predictors for 
response to dasatinib in lung cancer. One potential predictor 
is the Y472C mutation, which impairs BRAF kinase activ-
ity in several NSCLC cell lines with induction of senescence 
when exposed to dasatinib. The other predictor described is 
the mutation in the discoidin domain receptor 2 (DDR2) gene, 
which was found to be present in nine of 277 squamous cell 
carcinoma samples (3.2%) tested by Hammerman and col-
leagues.4 Squamous cell carcinoma cell lines harboring DDR2 
mutation were sensitive to dasatinib and nilotinib. A study is 
being planned to accrue patients with one of the nine known 
inactivation BRAF mutations in exons 11 and 15, including 
Y472C, or one of the 12 known DDR2 mutations. If three or 
more of the initial 12 patients respond to dasatinib 140 mg 
daily, the study will proceed to the second step with a total 
accrual of 25.
OPB51602
Signal transducer and activator of transcription-3 
(STAT-3) is constitutively active in most tumors but not in 
normal cells. STAT-3 activation through phosphorylation at 
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tyrosine 705 is regulated by several modulators including 
epidermal growth factor receptor (EGFR), Janus-activated 
kinases (JAK), extracellular signal-regulated kinase (ERK), 
and Src. Activated STAT-3 undergoes dimerization and trans-
location to the nucleus where it binds to STAT-responsive 
elements in the promoter of target genes leading to carcino-
genesis, proliferation, suppression of apoptosis, angiogenesis, 
metastases, and resistance to chemotherapy and radiation. 
Cancer cells with activating EGFR mutations may mediate 
some of their downstream effects through STAT-3. Activated 
STAT-3 (nuclear pSTAT-3) is expressed in approximately 55% 
of NSCLC tumors, being more common in adenocarcinomas 
and light smokers.5
Dr. Sequist presented the early findings of a phase I 
study evaluating OPB51602 in patients with advanced cancer. 
This drug inhibits the phosphorylation of STAT-3, preventing 
its activation and translocation to the nucleus. The primary 
objective was safety, and one patient with NSCLC achieved 
partial response (PR) at the dose of 5 mg daily.
APRICOXIB
Cyclooxigenase-2 (COX-2) is induced by tobacco car-
cinogens and epidemiological studies have suggested that 
individuals who routinely use nonsteroidal anti-inflammatory 
drugs have decreased risk of lung cancer. Overexpression of 
COX-2 is associated with poor prognosis in NSCLC, and 
COX-2 inhibitors have shown preclinical antitumor efficacy 
both as single agents and in combination with EGFR inhibi-
tors. One of the mechanisms for the synergy with EGFR 
inhibitors is the promotion of epithelial to mesenchymal 
transition by prostaglandin-E2 (PGE2), causing resistance to 
EGFR tyrosine kinase inhibitors. Urinary levels of the stable 
metabolite of PGE2 (PGE-M) correlates with intratumoral 
PGE2 levels, and the levels decrease with COX-2 inhibition. 
Because patients with suppressed PGE-M have superior out-
come, this molecule may represent a potential biomarker for 
COX-2 dependent disease and response to COX-2 inhibition. 
In a phase I study, the combination of apricoxib and erlotinib 
in patients with advanced NSCLC was well tolerated, with a 
disease control rate of 60% among the 27 enrolled patients (1 
PR and 11 SD).6 PGE-M was reduced in 70% of patients and 
among the 17 patients with elevated baseline PGE-M, 11 had 
clinical benefit.
Dr. Edelman presented the updated results of the 
Apricoxib with Tarceva in Non-Small-Cell Lung Cancer 
(APRiCOT-L) study, in which patients with previously treated 
advanced stage NSCLC were randomized to erlotinib alone at 
150 mg daily or in combination with apricoxib 400 mg daily. 
The primary endpoint was time to progression. Although 
there were no differences in outcomes between the arms for 
the entire cohort of patients, there was a small but statistically 
significant benefit from the doublet in patients younger than 
65 years, with improved time to progression from 1.4 to 2.7 
months (p = 0.018) and median OS from 3.8 to 8.5 months 
(p = 0.025). In contrast, the University of Maryland 
Greenbaum Cancer Center 0822 study showed no differences 
in OS between chemotherapy (pemetrexed or docetaxel) with 
or without apricoxib. The tumor expression of COX-2 was a 
predictor for benefit from the addition of celecoxib to chemo-
therapy in the Cancer and Leukemia B Group (CALGB) but 
not in the Nederlandse Vereniging voor Artsen Longziekten 
en Tuberculose (NVALT-4). The CALB 30801 is currently 
randomizing patients with immunohistochemistry COX-2 
index of 2 or higher to first-line chemotherapy with or without 
celecoxib.
CAMP RESPONSE ELEMENT-BINDING PROTEIN 
The cAMP response element-binding protein (CREB) 
is activated by hormones, retinoids, growth factors, and 
cytokines, and has a significant role in cellular growth, pro-
liferation, and survival. Dr. Koo reviewed the data on CREB 
in NSCLC, describing that this transcription factor is over-
expressed and active in NSCLC cell lines; phosphorylated 
CREB is associated with worse survival in NSCLC patients, 
and inhibition of CREB suppresses the growth of NSCLC cell 
lines both in vitro and in vivo.
CYCLINS INHIBITION BY RETINOIDS
There are two known families of retinoid receptors, 
the retinoid acid receptors and the retinoid X receptors, with 
the former endogenously activated by both all-trans-retinoid 
acid (RA) and 9-cis-RA, and the latter only by 9-cis-RA. 
Bexarotene is an oral synthetic retinoid that binds specifically 
to retinoid X receptors.
Dr. Dmitrovsky presented the data on targeting cyclins 
with the combination of bexarotene and erlotinib. Both drugs 
can suppress cyclin D1, which has much higher levels in 
EGFR mutant NSCLC cell lines than in wild type. In a phase 
II trial,7 among the 19 evaluable patients treated with the com-
bination of bexarotene and erlotinib, three patients achieved 
PR and six patients had SD.
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